Purpose: Diabetes mellitus is associated with an increased risk of cardiovascular disease. We compared the clinical effects of treating dyslipidemia in patients who had diabetes mellitus but no diagnosed cardiovascular disease with the effects of similar treatment in patients who had cardiovascular disease but no diabetes mellitus.
Methods: We estimated the number of adults (ages 30 to 74 years) requiring lipid therapy using data from the third National Health and Nutrition Examination Survey and current lipid treatment guidelines. Using the Cardiovascular Life Expectancy Model, we estimated the mean increase in life expectancy that would result from lowering low-density lipoprotein cholesterol levels by 35% and increasing high-density lipoprotein cholesterol levels by 8% based on results from the Scandinavian Simvastatin Survival Study.
Results: The mean number of years of life saved ranged from 3 to 3.4 years for men with diabetes versus 2.4 to 2.7 years for men with cardiovascular disease. In women, the estimated benefits were 1.6 to 2.4 years for those with diabetes versus 1.6 to 2.1 years for those with cardiovascular disease. Total population benefits were also substantial for patients with diabetes (25.4 million person-years of life saved) and those with cardiovascular disease (16.0 million person-years of life saved).
Conclusion: The clinical benefits of treating dyslipidemia in patients with diabetes should be at least equivalent to, if not more substantial than, the benefits observed among those with cardiovascular disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0002-9343(03)00303-6 | DOI Listing |
BMC Public Health
January 2025
Center for Global Health, Weill Cornell Medicine, 402 East 67 Street, 2 Floor, New York, NY, 10065, USA.
Background: Uncontrolled hypertension is the leading modifiable risk factor for cardiovascular disease mortality and remains high in low-middle income countries like Haiti. Barriers and facilitators to achieving hypertension control in urban Haiti remain poorly understood. Elucidating these factors could lead to development of successful interventions.
View Article and Find Full Text PDFInt J Emerg Med
January 2025
Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Background: Anticoagulants increase the risk of cardiac tamponade in patients with pericardial effusion (PE). Therefore, inappropriate administration of them in the presence of PE can lead to a catastrophic outcome. This study presents a patient with a provisional misdiagnosis of venous thromboembolism (VTE).
View Article and Find Full Text PDFJ Transl Med
January 2025
Department of Cardiology, Tongji Hospital, School of Medicine, Tongji University, No. 389 Xincun Road, Shanghai, 200065, China.
Background: Heavy metal exposure is an emerging environmental risk factor linked to cardiovascular disease (CVD) through its effects on vascular ageing. However, the relationship between heavy metal exposure and vascular age have not been fully elucidated.
Methods: This cross-sectional study analyzed data from 3,772 participants in the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2016.
BMC Musculoskelet Disord
January 2025
Department of Internal Medicine, Division of Rheumatology, Soonchunhyang University Seoul Hospital, Soonchunhyang University School of Medicine, Seoul, South Korea.
Background: Obstructive sleep apnea (OSA) is linked to various health conditions, including cardiovascular diseases and metabolic disorders. Hyperuricemia and gout may be associated with OSA, but large-scale studies on this are limited. This study aimed to investigate the association between hyperuricemia/gout and OSA using data from the Korea National Health and Nutrition Survey (KNHANES).
View Article and Find Full Text PDFBMC Public Health
January 2025
Department of Urology I, The First Hospital of Jilin University, Changchun, Jilin Province, 130021, China.
Background: Cardiovascular diseases (CVD) remain a significant global health burden, particularly in China, where kidney dysfunction (KD) is a key risk factor. This study analyzed trends in the burden of KD-induced CVD and subtypes among the working-age population (25-64 years) in China over the past 30 years and explored its association with age, period, and birth cohort.
Methods: This study extracted data from the Global Burden of Disease (GBD) 2021, focusing on deaths and disability-adjusted life years (DALYs) caused by KD-induced CVD and subtypes, including ischemic heart disease (IHD), stroke, and lower extremity peripheral artery disease (LEPAD) among 25-64 years globally and in China from 1992 to 2021.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!